help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Endocrinology, doi:10.1210/en.2005-0607
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
146/12/5188    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, Z.
Right arrow Articles by Swanson, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, Z.
Right arrow Articles by Swanson, S. M.
Endocrinology Vol. 146, No. 12 5188-5196
Copyright © 2005 by The Endocrine Society

Disruption of Growth Hormone Signaling Retards Early Stages of Prostate Carcinogenesis in the C3(1)/T Antigen Mouse

Zhuohua Wang, Gail S. Prins, Karen T. Coschigano, John J. Kopchick, Jeffrey E. Green, Vera H. Ray, Samad Hedayat, Konstantin T. Christov, Terry G. Unterman and Steven M. Swanson

Departments of Medicinal Chemistry and Pharmacognosy (Z.W., S.M.S.) and Urology (G.S.P.), Surgical Oncology (S.M.S., K.T.Ch.), Math, Statistics, and Computer Science (S.H.), and Medicine (T.G.U.), University of Illinois at Chicago, and Department of Veterans Affairs Jesse Brown Medical Center (T.G.U.), Chicago, Illinois 60612; Edison Biotechnology Institute and Department of Biomedical Sciences (K.T.Co., J.J.K.), Ohio University, Athens, Ohio 45701; Laboratory of Cell Regulation and Carcinogenesis (J.E.G.), National Cancer Institute, Bethesda, Maryland 20892; and Provident Hospital of Cook County (V.H.R.), Chicago, Illinois 60615

Address all correspondence and requests for reprints to: Steven M. Swanson, Department of Medicinal Chemistry and Pharmacognosy (M/C 781), University of Illinois at Chicago, 833 South Wood Street, Chicago, Illinois 60612-7231. E-mail: swanson{at}uic.edu.

Recent epidemiological studies suggest that elevated serum titers of IGF-I, which are, to a large degree, regulated by GH, are associated with an increase in prostate cancer risk. The purpose of the current study was to develop the first animal models to directly test the hypothesis that a normal, functional GH/IGF-I axis is required for prostate cancer progression. The GH receptor (GHR) gene-disrupted mouse (Ghr–/–), which has less than 10% of the plasma IGF-I found in GHR wild-type mice, was crossed with the C3(1)/T antigen (Tag) mouse, which develops prostatic intraepithelial neoplasia driven by the large Tag that progress to invasive prostate carcinoma in a manner similar to the process observed in humans. Progeny of this cross were genotyped and Tag/Ghr+/+ and Tag/Ghr–/– mice were killed at 9 months of age. Seven of eight Tag/Ghr+/+ mice harbored prostatic intraepithelial neoplasia lesions of various grades. In contrast, only one of the eight Tag/Ghr–/– mice exhibited atypia (P < 0.01, Fischer’s exact test). Disruption of the GHR gene altered neither prostate androgen receptor expression nor serum testosterone titers. Expression of the Tag oncogene was similar in the prostates of the two mouse strains. Immunohistochemistry revealed a significant decrease in prostate epithelial cell proliferation and an increase in basal apoptotic indices. These results indicate that disruption of GH signaling significantly inhibits prostate carcinogenesis.




This article has been cited by other articles:


Home page
Endocr Relat CancerHome page
S.-H. Tan and M. T Nevalainen
Signal transducer and activator of transcription 5A/B in prostate and breast cancers
Endocr. Relat. Cancer, June 1, 2008; 15(2): 367 - 390.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Anzo, L. J. Cobb, D. L. Hwang, H. Mehta, J. W. Said, S. Yakar, D. LeRoith, and P. Cohen
Targeted Deletion of Hepatic Igf1 in TRAMP Mice Leads to Dramatic Alterations in the Circulating Insulin-Like Growth Factor Axis but Does Not Reduce Tumor Progression
Cancer Res., May 1, 2008; 68(9): 3342 - 3349.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
Z. Wang, R. M. Luque, R. D. Kineman, V. H. Ray, K. T. Christov, D. D. Lantvit, T. Shirai, S. Hedayat, T. G. Unterman, M. C. Bosland, et al.
Disruption of Growth Hormone Signaling Retards Prostate Carcinogenesis in the Probasin/TAg Rat
Endocrinology, March 1, 2008; 149(3): 1366 - 1376.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
Q. Shen, D. D. Lantvit, Q. Lin, Y. Li, K. Christov, Z. Wang, T. G. Unterman, R. G. Mehta, and S. M. Swanson
Advanced Rat Mammary Cancers Are Growth Hormone Dependent
Endocrinology, October 1, 2007; 148(10): 4536 - 4544.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
J. D. McKay, R. Kaaks, M. Johansson, C. Biessy, F. Wiklund, K. Balter, H.-O. Adami, C. Boillot, L. Gioia-Patricola, F. Canzian, et al.
Haplotype-Based Analysis of Common Variation in the Growth Hormone Receptor Gene and Prostate Cancer Risk
Cancer Epidemiol. Biomarkers Prev., January 1, 2007; 16(1): 169 - 173.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
J. V. Silha, P. C. Sheppard, S. Mishra, Y. Gui, J. Schwartz, J. G. Dodd, and L. J. Murphy
Insulin-Like Growth Factor (IGF) Binding Protein-3 Attenuates Prostate Tumor Growth by IGF-Dependent and IGF-Independent Mechanisms
Endocrinology, May 1, 2006; 147(5): 2112 - 2121.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2005 by The Endocrine Society